Competing-risks regression models in analysis of biomarkers as predictors of high-risk human papillomavirus (HPV) infection outcomes and incident CIN in the LAMS cohort.

摘要: To assess the prediction potential of a 5-biomarker panel for detecting high-risk human papillomavirus (HR-HPV) infections and/or cervical intraepithelial neoplasia (CIN) progression. Five biomarkers, lipocalin, plasminogen activator inhibitor-2, p300, interleukin-10, and stratifin, were assessed in biopsies from 225 women Latin American Screening Study. Competing-risks regression models constructed to their predictive power (i) HR-HPV outcomes (negative, transient, or persistent infection) (ii) CIN (no progression, incident CIN1, CIN2, CIN3). LCN2, stratifin significantly associated with prevalent but lost significance multivariate analysis. In model, only p300 was an independent predictor CIN3 (odds ratio=2.63; 95% confidence interval, 1.05-6.61; P=0.039). univariate competing-risks regression, lipocalin predicted permanent HR-HPV-negative status, IL-10 emerged as HPV-negative status (subhazard ratio=4.04; 1.81-9.01; P=0.001). The clinical value predicting longitudinal infection is limited.